Unichem Laboratories Limited stock analysis
Want to see IN:UNICHEMLAB full AI Analyst Report?
Unichem Laboratories Limited (UNICHEMLAB) Stock Price & Analysis
UNICHEMLAB Stock Chart & Stats
- Day’s Range
- INR 481.50 - INR 493.25
- 52-Week Range
- INR 280.00 - INR 685.95
- Previous Close
- INR 498.05
- Volume
- N/A
- Average Volume (3M)
- 3,448
- Market Cap
- INR 34.21B
- Enterprise Value
- INR 41.85B
- Total Cash (Recent Filing)
- INR 1.60B
- Total Debt (Recent Filing)
- INR 4.98B
- Price to Earnings (P/E)
- 10.1
- Beta
- 1.17
- Next Earnings
- Feb 08, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Aug 01, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Low leverage and a growing equity base provide financial resilience and preserve flexibility to support operations or future investment. This conservative capital structure reduces balance-sheet strain and gives Unichem greater capacity to manage industry volatility over the next several quarters.
Recent Profitability Recovery
The return to profitability after losses indicates that earnings power has improved materially in the latest periods. If sustained, the recovery can strengthen internal funding, support product and market investment, and improve the company’s ability to compound results beyond the near term.
Diversified Pharmaceutical Portfolio
Exposure to branded formulations, generics, and APIs across multiple geographies gives Unichem several avenues for revenue generation rather than reliance on one product category or market. This breadth can support resilience as demand and competitive conditions vary across therapeutic and regional segments.
Bears Say
Weak Cash Conversion
Persistent negative operating and free cash flow means reported earnings are not translating reliably into cash resources. This can constrain internally funded growth, increase reliance on financial flexibility, and raise execution risk if investment needs remain high or operating conditions become less favorable.
Thin And Volatile Operating Profitability
A thin operating margin leaves limited room to absorb pricing pressure, cost changes, or execution setbacks. The earlier losses and sharp gross-margin fluctuations also indicate that recent earnings improvement may not yet represent a consistently stable profit profile over the coming periods.
Recent Revenue Contraction
The latest annual revenue decline interrupts the company’s prior expansion and signals weaker top-line momentum. Sustained contraction could limit operating leverage, reduce the scale benefits available to the business, and make it harder to maintain recent profitability improvements without further efficiency gains.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
What is Unichem Laboratories Limited’s market cap?
When is Unichem Laboratories Limited’s upcoming earnings report date?
How were Unichem Laboratories Limited’s earnings last quarter?
Is Unichem Laboratories Limited overvalued?
Does Unichem Laboratories Limited pay dividends?
What is Unichem Laboratories Limited’s EPS estimate?
How many shares outstanding does Unichem Laboratories Limited have?
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designed to treat numerous health conditions, including those related to gastroenterology, cardiovascular health, diabetes, mental health, neurological disorders, bacterial and other infectious diseases, and pain relief. Beyond these formulations, Unichem also provides active pharmaceutical ingredients (APIs) and offers contract manufacturing solutions. This enterprise was established in 1944 and operates from its corporate headquarters in Mumbai, India.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kalipada Bhattacharyya
- Employees
- 2,815
- Website
- www.unichemlabs.com
- Address
- 47, Kandivli Industrial Estate, Mumbai, MA, 400067, IN
Unichem Laboratories Limited (UNICHEMLAB) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 4 | 12 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 2 | 0 | 10 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:GUFICBIOGufic Biosciences Limited | ||
| IN:HIKALHikal Limited | ||
| IN:INDOCOIndoco Remedies Limited | ||
| IN:MOREPENLABMorepen Laboratories Limited | ||
| IN:WINDLASWindlas Biotech Ltd. |










